MDC’s work is supported by Innovate UK, one of the Mission’s national funders.
The Mission will develop tools to speed up the development of new dementia treatments in collaboration with industry and other UK initiatives, alongside boosting the number and speed of clinical trials in dementia.
MDC will lay a crucial foundation for the Dementia Mission: the ‘Neurodegeneration Initiative’ (NI). This is a new independent partnership engaging international industry and nationwide stakeholders that co-design and co-invest in the strategy for the Mission.
The NI will help others develop tools to identify at-risk patients, boost the number and speed of clinical trials in dementia, and bind global industry and partnerships to a range of UK initiatives.
By supporting the launch of the Mission, MDC will ensure it is able to deliver a transformative, industry-enabling approach to dementia research.
Professor Chris Molloy, CEO of Medicines Discovery Catapult, said:
“Medicines Discovery Catapult is proud to be trusted to support this major international initiative, which is another example of Catapults in action on behalf of the UK. As well as serving global industry with cutting-edge research and understanding, the Dame Barbara Windsor Dementia Mission will provide people living with dementia and their caregivers with much-needed hope for diagnosis and precision treatment for this devastating disease. MDC looks forward to working with all of the Mission’s many stakeholders to help bring a transformative approach to dementia R&D.
PACE (Pathways to Antimicrobial Clinical Efficacy) and the UK Health Security Agency (UKHSA) have released five new contemporary antimicrobial resistance (AMR) strain panels, giving innovators worldwide a resource to test novel therapeutics and diagnostics against today’s resistance patterns.
New appointments support MDC’s mission to turn drug discovery into commercial breakthroughs.
